Mutant PDGF-B as a VEGFR inhibitor

— Technology Description

Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesi…

Mutant PDGF-B as a VEGFR inhibitor

— Technology Description

Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesi…

Targeting TPL2 in RAS-mutated cancers

— Technology Description

Researchers in Kian-Huat Lim’s lab at Washington University have developed a therapeutic strategy to target TPL2 in RAS-mutated cancers, which should work synergistically with chemotherapy and radiation. As TPL2 (MAP3K8) is necessary for upstream activation of both MAP…

Create a Collection
Creating...